益杰立科丨 Epigenic

Public Releases Publications Events & Presentations

Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development

Aug 30，2023

SHANGHAI, China, August 30th, 2023 – Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has raised $32 million in Series A round of financing co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital.

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

Aug 07，2022

Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured $20 million in SeriesAngel andPre-A funding.